Bausch Health Announces Second Quarter 2024 Results
Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basis Consolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 million Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10% Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its second quarter 2024 financial results and other key updates from the quarter. "We continued our momentum in the second quarter, delivering our fifth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA, underscoring the strength of our product and geographic footprint and reinforcing our strategy.
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Red Alerts On Bausch Health Companies
Rumors circulated on a pre-packaged bankruptcy filing, which Bausch Health Companies quickly refuted. Bausch Health stock previously plummeted after posting Q1 results. BHC's cash flow remains weak, with concerns over long-term debt and limited resources for growth.
Bausch Health Stock Swings Wildly as it Addresses Report It's Considering Bankruptcy
It was quite a day for shares of Bausch Health Cos. (BHC), which were cut nearly in half before recovering as it addressed a research firm's report saying it was mulling bankruptcy options.
BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy
Specialty pharmaceutical and medical device firm Bausch Health (NYSE: BHC ) saw its shares tumble badly on Wednesday. Driving the negativity was a report by Reorg — billed as a global provider of credit intelligence, data and analytics for leveraged finance professionals — that the company was on the brink of bankruptcy.
Bausch Health denies report of bankruptcy filing
Bausch Health said on Wednesday it was not considering a bankruptcy or insolvency proceeding of any kind.
Bausch Health Responds to Market Rumors
LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources. The article contains unsubstantiated rumors, including that the Company is considering a bankruptcy or insolvency proceeding of any kind - it is not.
Bausch Health's stock halted for news, after tumbling more than 20%
Shares of Bausch Health Companies Inc. BHC, -21.60% have been halted for news, with the last trade at a 14-month low. The Canada-based drug and medical devices company's stock was down 21.6% when it was halted at 12:21 p.m.
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial results on Thursday, August 1, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
LAVAL, QC / ACCESSWIRE / June 20, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, today announced that it has filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Norwich Pharmaceuticals, Inc. This lawsuit was filed in connection with the Notice of Paragraph IV Certification, dated May 10, 2024, received from Norwich advising that it has submitted to the U.S. Food and Drug Administration (FDA) an amendment to an Abbreviated New Drug Application (ANDA) requesting approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Bausch Health continues to defend challenges to its XIFAXAN® intellectual property.
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare conferences. Bausch Health's gastroenterology (GI) business, Salix Pharmaceuticals presented data from its Amiselimod clinical trials at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on May 19, 2024, in Washington, D.C.
Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner
Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. The acquisition is not going well. Despite deploying substantial marketing expenses, Xiidra's revenue is mediocre and declining.
